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CORRESPONDENCE
Re: ‘Catheter-directed Foam Sclerotherapy of Great
Saphenous Veins in Combination with Pre-treatment
Reduction of the Diameter Employing the Principals of
Perivenous Tumescent Local Anesthesia’
We read with interest the article by Devereux et al.1 The
authors report no beneﬁt in terms of venous occlusion
using peri-saphenous ultrasound guided tumescence inﬁl-
tration (UGTI) in addition to long catheter foam sclero-
therapy (LCFS) of great saphenous veins (GSV).
The positive role of tumescence in foam sclerotherapy, to
decrease vein size, blood content, and inﬂow in the target
vein, has been highlighted previously.2,3 At the 2012 EVF
meeting, we presented a prospective comparative study,
which demonstrated better outcomes when UGTI was
added to LCFS of the GSV4 (82.4% occlusion rate after 14
months vs. 71% in patients treated without UGTI).
Firstly, the authors acknowledge adrenaline was not
included in the tumescent solution (because of legal issues).
In our experience with UGTI, adding a vasoconstricting
agent increases and prolongs GSV calibre reduction, and
this may explain our own better outcomes.
Furthermore, the statistical value of the study is possibly
biased by the quite small number of patients and by the
ﬁve patients (20%) and two patients (8%) not available
for 12-month follow-up in the non-UGTI/UGTI groups,
respectively.
We acknowledge that the positive effect of adding
tumescence to foam sclerotherapy has to be validated
through future studies on larger cohorts.
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Response to Letter to the Editor re “Catheter-directed
Foam Sclerotherapy of Great Saphenous Veins in
Combination with Pre-treatment Reduction of the
Diameter Employing the Principals of Perivenous
Tumescent Local Anesthesia”
Thank you very much for your letter that highlights the
positive effect of adding tumescence to foam sclerotherapy.
When we designed the study as a prospective random-
ized controlled pilot trial employing the use of drugs (poli-
docanol) we had to announce the protocol to the Federal
Institute for Drugs and Medical Devices (BfArM, Bonn,
Germany). This institute is deﬁned as an independent fed-
eral higher authority within the portfolio of the Federal
Ministry of Health. Following the device of the BfArM, we
were not allowed to use our standard tumescence local
anesthesia that we use routinely in endovenous thermal
ablation settings. In contrast we were explicitly allowed only
to inject saline solution perivenously. Maybe our results are
inﬂuenced by this restriction.
We agree that the effect of adding tumescence with
adrenaline (epinephrine) to foam sclerotherapy has to be
evaluated and validated in further studies.
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